Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silexion Therapeutics CorpSLXN · Entity 8506 | Director | February 20, 2026 | February 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silexion Therapeutics Corp
Report date February 20, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 8,237 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 7,576 · Balance 8,237 F1: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors. |
| Stock Option (right to buy Ordinary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-02-12 | Direct | 8,904 |
Reported balance
After 2026-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-20 · Grant · Acquired 8,904 · Balance 8,904 F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors. F3: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. |
| Stock Option (right to buy Ordinary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2035-02-09 | Direct | 780 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 780 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors.
F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors.
F3: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 23, 2026 16:11 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantStock Option (right to buy Ordinary Shares) · Derivative | 8,904 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001178913-26-000596 · zk2634424.xml · derivative · entry 2 Peled Amnon · CIK 0002048879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,904 Underlying: Ordinary Shares · 8,904 shares Expires 2036-02-12 F2 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors. F3 · derivative.exercise_date: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. F3 · derivative.expiration_date: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 16:11 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-000596 · zk2634424.xml · nonDerivative · entry 1 Peled Amnon · CIK 0002048879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,237 F1 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors. Read SEC document |
| February 09, 2025 Filed Dec 31, 2025 13:00 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantStock Option (right to buy Ordinary Shares) · Derivative | 780 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001178913-25-004143 · zk2534150.xml · derivative · entry 2 Peled Amnon · CIK 0002048879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780 Underlying: Ordinary Shares · 780 shares Expires 2035-02-09 F3 · derivative.exercise_price: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · shares: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F4 · derivative.exercise_date: All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date. F3 · derivative.underlying_shares: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · balance_after: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. Read SEC document |
| February 09, 2025 Filed Dec 31, 2025 13:00 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-25-004143 · zk2534150.xml · nonDerivative · entry 1 Peled Amnon · CIK 0002048879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 661 F1 · security: Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer, as consideration for the Reporting Person's service on the Issuer's board of directors. The shares subject to this award vest in full on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date. F1 · kind: Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer, as consideration for the Reporting Person's service on the Issuer's board of directors. The shares subject to this award vest in full on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date. F2 · shares: The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F2 · balance_after: The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.